CN1233373C - Chinese medicine comp osition for treating spondylodynia - Google Patents
Chinese medicine comp osition for treating spondylodynia Download PDFInfo
- Publication number
- CN1233373C CN1233373C CNB031340563A CN03134056A CN1233373C CN 1233373 C CN1233373 C CN 1233373C CN B031340563 A CNB031340563 A CN B031340563A CN 03134056 A CN03134056 A CN 03134056A CN 1233373 C CN1233373 C CN 1233373C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- grams
- olibanum
- myrrha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 241000717739 Boswellia sacra Species 0.000 claims description 11
- 239000004863 Frankincense Substances 0.000 claims description 11
- 241001057584 Myrrha Species 0.000 claims description 11
- 241000271039 Agkistrodon Species 0.000 claims description 10
- 241000131808 Scolopendra Species 0.000 claims description 10
- 241000522620 Scorpio Species 0.000 claims description 10
- 239000009490 scorpio Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 208000029761 vertebral disease Diseases 0.000 abstract 2
- 241000258920 Chilopoda Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 241000271897 Viperidae Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000035943 smell Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine composition for treating vertebra diseases, which is composed of long-node pit vipers, scorpions, centipedes, libanotus and myrrh. The Chinese medicine composition is an external applying medicine, and has ideal effects on treating various vertebra diseases without any side effect to the human body.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of vertebrae disease.
Background technology
Vertebra comprises: cervical vertebra, thoracic vertebra, lumbar vertebra, sacral and caudal vertebra.Be to connect by a kind of cushion that is shaped as disk between the above-mentioned vertebra diaphysis, supporting physical activity thus, and this cushion be intervertebral disc, its main effect is to bear pressure, and the buffering concussion also makes the vertebra activity freely.Just because of the important function of intervertebral disc, so, in case the intervertebral disc dislocation will influence the activity of limbs, we can say that disc disease is the main forms of vertebrae disease.And the main cause that this disease produces is to bear external pressure for a long time, and health is caught a cold, due to reason such as muscle spasm, aging and bony spur and other disease.
Mainly treat according to tcm therapy treatment disc disease by massage and oral medicine etc.Its treatment mechanism mainly is that dredging the meridian reaches therapeutic purposes with invigorating blood circulation.The main function of nervous system that adjusts of massage can not thoroughly cure disc disease; And oral Chinese medicine has various different formulations, and as " Chinese medicine preparation of treatment prolapse of lumbar intervertebral disc " of CN1065132C bulletin, this patent has mainly selected for use Radix Ginseng Rubra, Radix Notoginseng, Flos Carthami, eupolyphage sece steleophaga, Moschus, Resina Draconis, Myrrha, Olibanum 8 flavor raw material of Chinese medicine formulated.As seen, treating this kind disease has the plurality of Chinese combination formula, and the purpose of treatment also mainly is logical regulating menstruation arteries and veins, blood circulation promoting and blood stasis dispelling.Above-mentioned Chinese medicine preparation mostly is tens flavors or nearly tens Chinese medicines constitute, and the proportioning of its Chinese medicine component is also relatively complicated to be prepared with being difficult to.But, to the pharmaceutical composition of thorough treatment disc disease, particularly application compress now also among exploring.
Technical scheme
Task of the present invention provides a kind of Chinese medicine composition of curing vertebrae disease by simple formulation.
The Chinese medicine composition of treatment vertebrae disease proposed by the invention is made of Agkistrodon, Scorpio, Scolopendra, Olibanum, Myrrha, and the weight ratio of each component is an Agkistrodon: Scorpio: Scolopendra: Olibanum: Myrrha=1: 0.8-1.2: 0.4-0.6: 0.3-0.5: 0.5-0.7.According to putting down in writing in the Compendium of Material Medica: the Agkistrodon abnormal smells from the patient is sweet, and is salty, and temperature is poisonous, can treat diseases such as arthralgia, spasm of muscles and vessels; Scolopendra abnormal smells from the patient suffering, temperature, poisonous, cure mainly various poisonings; The Scorpio abnormal smells from the patient is sweet, hot, and is flat, poisonous, cures mainly all urticarias, apoplexy and hemiplegia, spasm of hands and feet etc.; Olibanum abnormal smells from the patient tepor, nontoxic, the main air noxious water is swollen, goes bad odor to remove oxious gas, and addiction is treated the poison of itching; The Myrrha bitter in the mouth, flat, nontoxic, cure mainly the removing blood stasis pain, treat the incised wound flogging injury, diseases such as all malignant boil anal fistula.
The weight proportion of this Chinese medicine composition each component is: Agkistrodon: Scorpio: Scolopendra: Olibanum: Myrrha=1: 0.8-1: 0.5-0.6: 0.3-0.5: 0.5-0.6.
Chinese medicine composition proposed by the invention is through showing with clinical research that to Cavia porcellus and the experiment of SD rat animal this Chinese medicine composition has tangible analgesia, antiinflammatory reaches the therapeutical effect to soft tissue injury.In the skin allergy experiment, it is three groups that 30 Cavia porcelluss are divided into, and one group for adopting the present invention; Two groups are adopted the plaster substrate group; Three groups of positive matched groups (adopting the 2.4-dinitrochlorobenzene to dissolve in plaster substrate with 1% sensitization concentration), experiment show that Cavia porcellus does not have irritated phenomenon (referring to table 1) takes place.In addition, also 80 SD rats have been carried out secular toxicity test with Chinese medicine composition proposed by the invention, be about to rat and be divided into 4 groups (referring to table 2) by weight, every day, administration was respectively 0.25g/Kg, 0.5g/Kg, 1.0g/Kg, change dressings every day once, successive administration 90 days shows all in range of normal value through blood biochemical indicator continuous monitoring result, learns by statistics and handles no significant difference between each group.And there is no drug-induced overt toxicity pathological change (referring to table 2) through the rat pathological examination is also demonstrated Rats Organs and Tissues.Utilize Chinese medicine composition proposed by the invention through to long-term heavy dose of use of animal simultaneously, hemogram, blood biochemical, pathology detection be there is no obvious change, do not see obvious toxic-side effects.
Chinese medicine composition proposed by the invention suffers from lumbago and/or sciatica to 492 examples, and the cervical vertebra pain patient carries out clinical treatment.In treatment, external application every day said composition portion, one month is a course of treatment, treats 2-3 the course of treatment.In late result observation, drug withdrawal 1 year and allergy and toxic and side effects do not occur after statistics shows that total effective rate reaches more than 93%.
Table 1 the present invention is to the skin allergy experiment of Cavia porcellus
| Group | The example number | Sensitization rate (%) | The average response value | |||
| 6 hours | 24 hours | 48 hours | 72 hours | |||
| Of the present invention group | 10 | 0 | 0 | 0 | 0 | 0 |
| Plaster base value group | 10 | 0 | 0 | 0 | 0 | 0 |
| Positive controls | 10 | 100 | 1 | 0.96 | 0.72 | 0 |
The influence that table 2 the present invention causes rat long term toxicity internal organs (X ± S)
| Internal organs | Date | Matched group | Small dose group | Middle dosage group | Heavy dose of group |
| The heart | D60 | 0.49±0.03 | 0.45±0.05 | 0.46±0.05 | 0.47±0.06 |
| D82 | 0.48±0.04 | 0.38±0.03 | 0.42±0.06 | 0.43±0.05 | |
| Liver | D60 | 3.8±0.3 | 3.5±0.3 | 3.5±0.3 | 3.5±0.3 |
| D82 | 3.5±0.4 | 3.9±0.3 | 3.3±0.5 | 3.6±0.4 | |
| Spleen | D60 | 0.289±0.04 | 0.282±0.07 | 0.284±0.05 | 0.270±0.04 |
| D82 | 0.264±0.11 | 0.289±0.03 | 0.238±0.04 | 0.253±0.06 | |
| Lung | D60 | 0.94±0.26 | 0.80±0.49 | 0.58±0.09 | 0.59±0.12 |
| D82 | 0.65±0.31 | 0.58±0.08 | 0.58±0.09 | 0.58±0.07 | |
| Kidney | D60 | 0.99±0.99 | 0.85±0.05 | 0.43±0.06 | 0.45±0.06 |
| D82 | 0.34±0.09 | 0.75±0.06 | 0.75±0.06 | 0.74±0.05 | |
| The adrenal gland | D60 | 0.033±0.01 | 0.029±0.01 | 0.025±0.01 | 0.028±0.01 |
| D82 | 0.033±0.01 | 0.032±0.01 | 0.029±0.01 | 0.030±0.01 | |
| Brain | D60 | 0.69±0.11 | 0.68±0.12 | 0.62±0.16 | 0.65±0.13 |
| D82 | 0.66±0.09 | 0.65±0.14 | 0.56±0.12 | 0.63±0.11 | |
| Testis | D60 | 1.42±0.15 | 1.38±0.14 | 1.45±0.15 | 1.40±0.12 |
| D82 | 1.43±0.15 | 1.32±0.15 | 1.29±0.07 | 1.31±0.09 | |
| The uterus | D60 | 0.46±0.13 | 0.42±0.05 | 0.38±0.08 | 0.39±0.09 |
| D82 | 0.46±0.08 | 0.40±0.08 | 0.35±0.04 | 0.35±0.07 |
The specific embodiment:
Embodiment 1: get Agkistrodon 100 grams, Scorpio 80 grams, Scolopendra 60 grams, Olibanum 50 grams, Myrrha 60 grams, it is even that said medicine is pulverized the back remix separately, and be divided into 350 parts after making paste, and each administration portion spreads on the affected part outward.
Embodiment 2: get Agkistrodon 100 gram, Scorpio 100 grams, Scolopendra 50 grams, Olibanum 40 grams, Myrrha 70 grams, be divided into 350 parts after making paste as stated above, usage is the same.
Embodiment 3: get Agkistrodon 100 gram, Scorpio 110 grams, Scolopendra 60 grams, Olibanum 30 grams, Myrrha 50 grams, be divided into 350 parts after making paste as stated above, usage is the same.
Claims (2)
1, a kind of Chinese medicine composition for the treatment of vertebrae disease, it is characterized in that: said composition is made of Agkistrodon, Scorpio, Scolopendra, Olibanum, Myrrha, wherein, the weight ratio of each component is in the said composition: Agkistrodon: Scorpio: Scolopendra: Olibanum: Myrrha=1: 0.8-1.2: 0.4-0.6: 0.3-0.5: 0.5-0.7.
2, Chinese medicine composition according to claim 1 is characterized in that: the weight proportion of this Chinese medicine composition each component is: Agkistrodon: Scorpio: Scolopendra: Olibanum: Myrrha=1: 0.8-1: 0.5-0.6: 0.3-0.5: 0.5-0.6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031340563A CN1233373C (en) | 2003-09-25 | 2003-09-25 | Chinese medicine comp osition for treating spondylodynia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031340563A CN1233373C (en) | 2003-09-25 | 2003-09-25 | Chinese medicine comp osition for treating spondylodynia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1528355A CN1528355A (en) | 2004-09-15 |
| CN1233373C true CN1233373C (en) | 2005-12-28 |
Family
ID=34286118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031340563A Expired - Fee Related CN1233373C (en) | 2003-09-25 | 2003-09-25 | Chinese medicine comp osition for treating spondylodynia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1233373C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288758B (en) * | 2008-06-06 | 2012-02-08 | 马新民 | Analgesic medicine |
| CN102727601B (en) * | 2011-04-12 | 2014-02-12 | 罗伟雄 | External patch for treating prolapse of lumbar intervertebral disc |
-
2003
- 2003-09-25 CN CNB031340563A patent/CN1233373C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1528355A (en) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1272066C (en) | Medicinal composition for relieving itching | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN1233373C (en) | Chinese medicine comp osition for treating spondylodynia | |
| CN1824194A (en) | Pure Chinese medicine external use body fat reducing medicine | |
| CN115414456B (en) | Traditional Chinese medicine composition for treating hemorrhoids and application thereof | |
| CN104474108A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and preparation method of traditional Chinese medicine preparation | |
| CN100482295C (en) | Bee-glue medicinal cervical vertebrae pillow | |
| CN101797371B (en) | Drug combination for weight-reducing massage | |
| CN107898989A (en) | A kind of Chinese medicine composition for treating obstructive sleep apnea syndrome and preparation method thereof | |
| CN102908582A (en) | Traditional Chinese medicine composition for treating blood stasis type abdominal mass for women and preparation method thereof | |
| CN108066572B (en) | Plaster for treating gonarthromeningitis and preparation method thereof | |
| CN1131051C (en) | medicine for treating cervical spondylosis and preparation method thereof | |
| CN108904705A (en) | A kind of Chinese medicine composition for treating postmenopausal women gouty arthritis,chronic | |
| CN116763882B (en) | Sanjiu plaster and preparation method and application thereof | |
| CN1047947C (en) | Ointment for bone tuberculosis and its preparation technology | |
| CN102512505B (en) | Chinese patent medicine for treating bone spur | |
| CN108310163A (en) | A kind of dispelling wind-evil and wetness-evil blood-activating Chinese medicine preparation and preparation method thereof | |
| RU2076731C1 (en) | Agent and method of organism nonspecific resistance increase at viscera morbidity | |
| CN1315200A (en) | A kind of external medicine for treating prolapse of lumbar intervertebral disc | |
| CN118416187A (en) | A Chinese medicinal composition for use in the season of Sanfuzhu with effects of invigorating spleen, eliminating dampness and dispelling cold, and its preparation method | |
| CN1329061C (en) | Medicating moxibustion musk bolus and its prepn | |
| CN117045765A (en) | Allergic rhinitis patch and preparation method thereof | |
| CN111617182A (en) | Muscle-relaxing and collateral-activating vitality activating cream and preparation method thereof | |
| CN118105443A (en) | Traditional Chinese medicine composition for treating lumbago | |
| CN118356460A (en) | Traditional Chinese medicine prescription for treating functional constipation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |